Finance

Beta
Lists
KYTX:NASDAQ
Kyverna Therapeutics Inc
USD 8,06
+2,35%
(+0,19) 1D
12 Jun., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYTX...
Open
USD 7,90
High
USD 8,44
Low
USD 7,86
Mkt. cap
489,71 m
Avg. vol.
829,18 k
Volume
646,65 k
52-wk high
USD 13,67
52-wk low
USD 2,52
EPS
-USD 3,28
Shares outstanding
60,80 m
No. of employees
129
Open
USD 7,90
High
USD 8,44
Low
USD 7,86
Mkt. cap
489,71 m
Avg. vol.
829,18 k
Volume
646,65 k
52-wk high
USD 13,67
52-wk low
USD 2,52
EPS
-USD 3,28
Shares outstanding
60,80 m
No. of employees
129
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to KYTX in the past 3 months
Strong Buy
Buy
5
Hold
0
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KYTX in the last 3 months.
Highest
Current USD 8,06
USD 33,00 (+309,68%)
Average
USD 30,00 (+272,44%)
Lowest
USD 25,00 (+210,37%)
News stories
From sources across the web
About Kyverna Therapeutics Inc
CEO-
Employees129
Founded2018
HeadquartersEmeryville, Kalifornië, Verenigde State van Amerika
Sector-
Websitekyvernatx.com
Last report
12 Mei 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-USD 0,66 / -USD 0,73
+9,70%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
-
-
-
-
Cost of goods sold
35,82 m
30,46 m
30,01 m
30,07 m
Cost of revenue
35,82 m
30,46 m
30,01 m
30,07 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,59 m
8,27 m
9,27 m
11,29 m
Operating expense
8,59 m
8,27 m
9,27 m
11,29 m
Total operating expenses
44,41 m
38,73 m
39,28 m
41,37 m
Operating income
-44,41 m
-38,73 m
-39,28 m
-41,37 m
Other non operating income
-21,00 k
-53,00 k
17,00 k
-21,00 k
EBT including unusual items
-42,08 m
-36,79 m
-37,80 m
-39,73 m
EBT excluding unusual items
-42,08 m
-36,79 m
-37,80 m
-39,73 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-42,08 m
-36,79 m
-37,80 m
-39,73 m
Net profit margin
-
-
-
-
Earnings per share
-0,97
-0,85
-0,80
-0,66
Interest and investment income
2,36 m
2,00 m
1,90 m
2,33 m
Interest expense
-14,00 k
-7,00 k
-444,00 k
-667,00 k
Net interest expenses
2,35 m
1,99 m
1,46 m
1,66 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-44,37 m
-37,84 m
-38,91 m
-41,02 m
Gain or loss from assets sale
-
40,00 k
20,00 k
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer